<DOC>
	<DOCNO>NCT00897871</DOCNO>
	<brief_summary>RATIONALE : Studying sample blood laboratory young patient cancer may help doctor learn carboplatin , cyclophosphamide , etoposide affect body patient respond treatment . PURPOSE : This laboratory study evaluate side effect well anticancer drug work young patient cancer .</brief_summary>
	<brief_title>Evaluating Side Effects How Well Anticancer Drugs Work Very Young Patients With Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Investigate inter-individual variability pharmacokinetics select anticancer drug infant child age &lt; 2 year current dosing schedule . - Compare drug exposure degree pharmacokinetic variability child &lt; 2 year data obtain publish study old child . - Relate inter-individual variability pharmacokinetics drug exposure clinical toxicity response . - Use pharmacokinetic data conjunction clinical information obtain follow treatment investigate suitability current dosing regimen infant young child . OUTLINE : This multicenter study . Patients stratify accord age month ( 0 6 v 6 12 v 12 24 ) . Patients receive carboplatin , cyclophosphamide , etoposide accord dose regimen detail clinical protocol child treat . Blood sample collect patient receive 1 3 drug central venous catheter periodically treatment measure pharmacokinetics specific drug . Additional blood sample collect DNA extraction polymorphism analysis CYP2B6 , CYP2C9 , metabolize enzyme addition determination genetic variation multiple drug resistance .</detailed_description>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis childhood cancer Receiving carboplatin , cyclophosphamide , etoposide standard treatment part clinical study Children 's Cancer Leukemia Group ( CCLG ) center PATIENT CHARACTERISTICS : Not specify PRIOR CONCURRENT THERAPY : Single double lumen central venous catheter place No concurrent anticonvulsant , azole antifungal agent , chronic steroid treatment</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>2 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>unspecified childhood solid tumor , protocol specific</keyword>
</DOC>